International journal of general medicine
Predictive Performance of a Serum sRAGE/sVEGFR-3 Dual-Biomarker Combination for Hypercoagulability Status in Pediatric Mycoplasma pneumoniae Pneumonia: A Retrospective Cohort Analysis
By Guo C, Cheng F, Sun S and 3 others.
Abstract
Objective
To evaluate serum soluble receptor for advanced glycation end products (sRAGE) and soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) as biomarkers for hypercoagulable state in children with Mycoplasma pneumoniae pneumonia (MPP).
Methods
We retrospectively enrolled 352 children with MPP (hypercoagulable, n=98; non-hypercoagulable, n=254). Serum sRAGE and sVEGFR-3 were measured by enzyme-linked immunosorbent assay (ELISA). Spearman analysis, Box-Tidwell test, and restricted cubic splines (RCS) assessed correlations/nonlinear effects; least absolute shrinkage and selection operator (LASSO) regression selected variables; multivariable logistic regression analyzed risk factors (variance inflation factor [VIF] for multicollinearity); receiver operating characteristic (ROC) curve analysis evaluated predictive value (Youden index cut-off); Bootstrap (1000 iterations) validated internally; net reclassification improvement (NRI) and integrated discrimination improvement (IDI) assessed incremental value.
